Full text

Turn on search term navigation

Copyright © 2019 Thushani Siriwardhane et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Even though most thyroid subjects are undiagnosed due to nonspecific symptoms, universal screening for thyroid disease is not recommended for the general population. In this study, our motive is to showcase the early appearance of thyroid autoantibody, anti-TPO, prior to the onset of thyroid hormone disruption; hence the addition of anti-TPO in conjunction with traditional thyroid markers TSH and FT4 would aid to reduce the long-term morbidity and associated health concerns. Here, a total of 4581 subjects were tested multiple times for TSH, FT4, anti-TPO, and anti-Tg and followed up for 2 years. We streamlined our subjects into two groups, A1 (euthyroid at first visit, but converted to subclinical/overt hypothyroidism in follow-up visits) and A2 (euthyroid at first visit, but converted to hyperthyroidism in follow-up visits). According to our results, 73% of hypothyroid subjects (from group A1) and 68.6% of hyperthyroid subjects (from group A2) had anti-TPO 252 (±33) and 277 (±151) days prior to the onset of the thyroid dysfunction, respectively. Both subclinical/overt hypothyroidism and hyperthyroidism showed a significantly higher percentage of subjects who had anti-TPO prior to the onset of thyroid dysfunction compared to the combined control group. However, there was no significant difference in the subjects who had anti-Tg earlier than the control group. Further assessment showed that only anti-TPO could be used as a standalone marker but not anti-Tg. Our results showcase that anti-TPO appear prior to the onset of thyroid hormone dysfunction; hence testing anti-TPO in conjunction with TSH would greatly aid to identify potentially risk individuals and prevent long-term morbidity.

Details

Title
Significance of Anti-TPO as an Early Predictive Marker in Thyroid Disease
Author
Siriwardhane, Thushani 1   VIAFID ORCID Logo  ; Krishna, Karthik 2 ; Ranganathan, Vinodh 2 ; Jayaraman, Vasanth 2 ; Wang, Tianhao 2 ; Kang, Bei 2 ; Ashman, Sarah 1 ; Rajasekaran, Karenah 2 ; Rajasekaran, John J 2 ; Krishnamurthy, Hari 2   VIAFID ORCID Logo 

 Vibrant America LLC., San Carlos, CA, USA 
 Vibrant Sciences LLC., San Carlos, CA, USA 
Editor
Ricard Cervera
Publication year
2019
Publication date
2019
Publisher
John Wiley & Sons, Inc.
ISSN
20900422
e-ISSN
20900430
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2410321089
Copyright
Copyright © 2019 Thushani Siriwardhane et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.